Melbourne, Apr 17, 2008 (ABN Newswire) - Australia’s adult stem cell company, Mesoblast Limited (ASX: MSB; USOTC: MBLTY), today announced successful long-term results in its osteoarthritis preclinical trials. A single injection of its proprietary allogeneic, or “off-the-shelf”, adult stem cells into arthritic knees provided sustained protection against cartilage destruction and degeneration for up to nine months.
